In the patient group, ISG20 levels were lower in CHB patients compared to patients with only HCC (16.4 ng/mL vs. 21.2 ng/ml, P=0.022) and those with LC plus HCC (16.4 ng/mL vs. 24.5 ng/ml, P<0.0001). Here, ISG20 is linked to hepatocellular carcinoma.